SELLAS Shares Skyrocket 177% After Positive Phase 3 AML Data with 41 Percent Survival Benefit
SELLAS Life Sciences (SLS) announces positive Phase 3 REGAL trial results for GPS in AML, showing a 41% reduction in risk of death and 24.0 month median survival.









